Creating the EUDAMED database, a project of the European Commission, has been an onerous and lengthy task. Originally planned to be operational by 2020, the updated completion is projected for 2024, two years after the application of the IVD Regulation (IVDR). This delay will cause a potential knowledge and practice gap for IVD stakeholders that is bridged by the publication of MDCG 2022-12.
Role of the MDCG and the New Document
Supporting the European Commission with MDR and IVDR implementation issues is the main role of the MDCG, which publishes explanatory documents such as MDCG 2022-12. Medical device manufacturers are already familiar with this type of “alternative solutions” guidance, as MDCG released a similar document in May 2021 for further clarification under MDR.
Provisions related to the use of Eudamed (as referred to in Art. 113 (3) (f) IVDR)
Alternative solutions to submit and/or exchange information (as required under the IVDR)
Responsible actor(s)
Article 36: Nomination of experts for joint assessment of applications for notification
2. The Commission shall maintain a list of the experts nominated pursuant to paragraph 1 of this Article, together with information on their specific field of competence and expertise…
Paragraph 2: The Commission has made available the list to Member States by means of a dedicated secure directory in the Communication and Information Resources Centre for Administrations, Businesses and Citizens (CircaBC).
Commission (CircaBC)
EUDAMED Functionality
Of EUDAMED’s six reporting modules, three are currently available voluntarily. They are 1) Actor Registration, 2) Notified Bodies and Certificates, and 3) Unique Device Identifiers (UDI) and Device Registration.
Once fully operational, EUDAMED there will be two reporting deadlines. Six months after its release, requirements will be mandatory for the following: Actor Registration, Vigilance, Clinical Investigation and Performance Studies, and Market Surveillance. Twenty-four months after release, requirements will be mandatory for the remaining two modules: UDI/Device Registration, and Notified Bodies and Certificates.
The Future of EUDAMED
According to Medtech Insight, “from the moment the Eudamed notice is published, “new” data must be entered. New data may relate to a new device, but may also refer to a vigilance report of any device on the market. But before any information can be entered into the database, all economic operators, devices, certificates, etc, need to be registered.”
They further elaborate, “within six months of the Eudamed notice being published, certain functionalities, including the following, will become available: registration of economic operators (MDR Article 31); registration of summary of safety and clinical performance (SSCP) (Article 32); clinical investigations applications (Articles 70-77); registration of serious incidents and field safety corrective actions; and final report of investigations (Article 87(1) and 89(5)).”
Does your organization need support for MDR related submissions including CER, CEP, PMCF plans or reports? Or IVDR related submissions like PER, PEP, SVR, CPR, or PMPF plans or reports? Criterion Edge has the expertise and bandwidth to work with you and get the job done. We have expert medical writers to support your organization in developing the necessary documents to ensure a smooth transition and meet these fast-moving deadlines. Get a free consultation today.
[Free Webinar] IVDR Readiness: Creating a Blueprint to Build a Strong PER
Join us on Wednesday, June 7th, 2023 at 11 AM PST, as our regulatory experts discuss the process of writing a PER, with careful attention to the importance of aligning technical documents to create a cohesive, well-organized report.
Fill out this form, or contact us at info@criterionedge.com, and we would be happy to answer any of your questions as well as book you an appointment to discuss your project needs during a time that works for you.
Are You Reg. Ready? Get your medical affairs team primed to manage new regulatory requirements
In this discussion, we provide an overview of how to plan and coordinate change within an organization to meet upcoming EU IVDR regulatory requirements. We will be highlighting key steps involved in helping medical affairs transition to a more rigorous regulatory environments, and how to evaluate talent gaps, team leadership composition, and process challenges of your product portfolio.
Driving Innovation to Success in the Market: Strategic Considerations
In this discussion, our panel of proven leaders discuss the key elements that support and propel the innovation process in the medical device, pharmaceutical, and IVD industries. We will be highlighting key areas of the process, important players in the pathway to the market, and how successful innovations spawn new innovations in new markets such as the digital health space, and more.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Tag Manager and Pardot's tracking features to collect information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!